Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037020 | 0.87 | SMN1; SMN2 (0.43) | ALDH1A1ALOX12LMNARAB9ASMN1; SMN2 | |
| SCHEMBL10015377 | 0.78 | SMN1; SMN2 (0.41) | ALDH1A1ALOX12LMNARAB9ASMN1; SMN2 | |
| SCHEMBL871729 | 0.78 | ALDH1A1 (0.44) | ALDH1A1ALOX12LMNARAB9ASMN1; SMN2 | |
| SCHEMBL16405303 | 0.77 | RAB9A (0.40) | ALDH1A1ALOX12LMNARAB9ASMN1; SMN2 | |
| SCHEMBL16841649 | 0.74 | TSHR (0.42) | ALDH1A1ALOX12LMNARAB9ASMN1; SMN2 | |
| SCHEMBL13907969 | 0.74 | ALDH1A1 (0.43) | ALDH1A1ALOX12LMNARAB9ASMN1; SMN2 | |
| SCHEMBL13400049 | 0.73 | ALDH1A1 (0.41) | ALDH1A1ALOX12LMNARAB9ASMN1; SMN2 | |
| SCHEMBL18825259 | 0.72 | FAAH (0.40) | ALDH1A1ALOX12RAB9ASMN1; SMN2HPGD | |
| SCHEMBL11007672 | 0.72 | LMNA (0.42) | ALDH1A1LMNARAB9ASMN1; SMN2TSHR | |
| SCHEMBL31440989 | 0.72 | SLC22A6 (0.42) | ALDH1A1ALOX12LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2478049-B1 | A POLYMER SUPPORT | UNIV CAPE TOWN (ZA) | 2015-02-25 | — | — | EP | claimed |
| WO-2011159735-A2 | TETRANOR-PGDM/PGJM SPECIFIC IMMUNOGENS, ANTIBODIES, TRACERS, ASSAY KITS AND METHODS FOR MAKING SAME | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2011-12-22 | — | — | WO | claimed |
| CN-101189519-A | Biological indicator | STERIS INC (US) | 2008-05-28 | — | — | CN | claimed |
| US-20230026348-A1 | NITROXYLATED PROTEINS AND METHODS FOR THE USE THEREOF | SCHINDLER, WILLIAM | 2023-01-26 | — | — | US | disclosed |
| US-11359004-B2 | Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins | Schindler, William (US) | 2022-06-14 | — | — | US | disclosed |
| EP-2830638-B1 | DIASPIRIN CROSSLINKED PEGYLATED HEMOGLOBIN | SCHINDLER WILLIAM (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10357457-B2 | Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells | RODOS BIOTARGET GMBH (DE) | 2019-07-23 | — | — | US | disclosed |
| US-20190127445-A1 | SUCCINIMIDE-ACTIVATED NITROXYL COMPOUNDS AND METHODS FOR THE USE THEREOF FOR NITROXYLATION OF PROTEINS | SCHINDLER, WILLIAM | 2019-05-02 | — | — | US | disclosed |
| EP-2834329-B1 | SUCCINIMIDE-ACTIVATED NITROXYL COMPOUNDS AND METHODS FOR THE USE THEREOF FOR NITROXYLATION OF PROTEINS | SCHINDLER WILLIAM (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10029001-B2 | Diaspirin crosslinked pegylated hemoglobin | Schindler, William (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2150282-B1 | COMPOSITIONS AND METHODS FOR SCAFFOLD FORMATION | REGENTIS BIOMATERIALS LTD (IL) | 2018-04-11 | — | — | EP | disclosed |
| EP-0552280-B1 | INHIBITION OF VIRAL REPLICATION | VESTAR INC (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5419914-A | Drug delivery | VESTAR, INC. (US) | 1995-05-30 | — | — | US | disclosed |
| US-5399331-A | Drug delivery, medical diagnosis | THE LIPOSOME COMPANY, INC. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0555317-B1 | PHOSPHOLIPID ANALOGUE VESICLE WITH A SUCCINIMIDYL MOIETY | VESTAR INC (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0555317-A1 | PHOSPHOLIPID ANALOGUE VESICLE WITH A SUCCINIMIDYL MOIETY. | VESTAR INC (US) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992005773-A1 | PHOSPHOLIPID ANALOGUE VESICLE WITH A SUCCINIMIDYL MOIETY | VESTAR, INC. (US) | 1992-04-16 | — | — | WO | disclosed |
| WO-1992006192-A1 | INHIBITION OF VIRAL REPLICATION | VESTAR, INC. (US) | 1992-04-16 | — | — | WO | disclosed |
| US-5080896-A | Adjuvant Coupled to Antigen | AKZO N. V. (NL) | 1992-01-14 | — | — | US | disclosed |
| WO-1991000289-A2 | TARGETED LIPOSOMES AND METHODS FOR LIPOSOME-PROTEIN COUPLING | THE LIPOSOME COMPANY, INC. (US) | 1991-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029001-B2 | Diaspirin crosslinked pegylated hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1707/4885ALOX12 393/4885LMNA 2606/4885 |
| US-20190127445-A1 | SUCCINIMIDE-ACTIVATED NITROXYL COMPOUNDS AND METHODS FOR THE USE THEREOF FOR NITROXYLATION OF PROTEINS | PPOX, QSOX1, HMOX2 | ALDH1A1 2576/4885ALOX12 589/4885LMNA 1731/4885 |
| US-20230026348-A1 | NITROXYLATED PROTEINS AND METHODS FOR THE USE THEREOF | PPOX, MB, HMOX2 | ALDH1A1 2500/4885ALOX12 414/4885LMNA 1525/4885 |
| US-11359004-B2 | Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins | PPOX, QSOX1, HMOX2 | ALDH1A1 2576/4885ALOX12 589/4885LMNA 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.